All In Biotech

Drug Trial Radar · NCT00001160

Studies on Tumors of the Thyroid

Studies on Thyroid Nodules and Thyroid Cancer

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

2,500

Planned (sponsor's estimate)

Start

Jun 1, 1977

Primary completion

Not stated

Sponsor

Sponsor type
NIH
First posted
Nov 4, 1999

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 6 months, up to 98 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Participants in this study will be patients diagnosed with or suspected to have a thyroid nodule or thyroid cancer. The main purpose of this study is to further understand the methods for the diagnosis and treatment of thyroid nodules and thyroid cancer. Many of the test performed are in the context of standard medical care that is offered to all patients with thyroid nodules or thyroid cancer. Other tests are performed for research purposes. In addition, blood and tissue samples will be taken for research and genetic studies.

Conditions

  • Hurthle Cell Thyroid Cancer
  • Tall Cell Variant Thyroid Cancer
  • Follicular Thyroid Cancer
  • Thyroid Cancer
  • Papillary Thyroid Cancer

Interventions

  • 68-Gallium DotatateDrug

    For evaluation risk/benefit evaluation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of thyroid cancerTime frame: As clinically indicated
  2. Evaluation of thyroid disordersTime frame: As clinically indicated

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institutes of Health Clinical Center

    Bethesda, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.